The Guardian and other news source reported that a team of Swiss scientists has developed a vaccine that targets angiotensin II to reduce blood pressure significantly.
The findings, published in The Lancet, were based on a 14 week multicentre, double-blind, randomised, placebo-controlled trial involving 72 patients with mild-to-moderate hypertension. The patients received randomly injections of either 100 μg or 300 μg of the vaccine or placebo.
The researchers found that systolic and diastolic blood pressure fell by 9mm and 4mm respectively in patients given 300 μg of the vaccine, especially in the morning, but no change in blood pressure in the placebo group. They said the findings were promising but large-scale trials were needed.
Source: "Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study" The Lancet 2008; 371:821-827 Number 9615 ( full text via Athens)
No comments:
Post a Comment